Cycuria Therapeutics is a preclinical-stage oncology start-up based in Graz, Austria. Founded in 2024 by leading scientists from the Medical University of Graz, Technical University of Munich and University of Heidelberg, our mission is to develop breakthrough therapies for hematological cancers, with the potential to expand into solid tumors. At Cycuria, we combine a deep mechanistic understanding of a specific human cytokine with cutting-edge protein engineering to develop first-in-class biologics. Our therapeutic approach selectively targets leukemic tumor cells and their progenitor stem cells, while preserving—and even enhancing—the viability and function of healthy blood cells. By offering a novel therapeutic approach that delivers both excellent tolerability and long-lasting efficacy, we aim to meet the significant unmet needs in cancer treatment and provide new hope where conventional therapies have fallen short.

The managing directors are Prof. Philipp Jost and Dr. Nisit Khandelwal.